Inhaled Δ9-tetrahydrocannabinol does not enhance oxycodone-induced respiratory depression: randomised controlled trial in healthy volunteers
British Journal of Anaesthesia · 2023
DOI: 10.1016/j.bja.2022.12.018 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Anaesthesia, 2023. Verfasst von Cornelis Jan van Dam und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Cannabis, Respiratory Insufficiency. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: In humans, the effect of cannabis on ventilatory control is poorly studied, and consequently, the effect of Δ9-tetrahydrocannabinol (THC) remains unknown, particularly when THC is combined with an opioid. We studied the effect of THC on breathing without and with oxycodone pretreatment. We hypothesised that THC causes respiratory depression, which is amplified when THC and oxycodone are combined. METHODS: In this randomised controlled crossover trial, healthy volunteers were administered inhaled Bedrocan® 100 mg (Bedrocan International B.V., Veendam, The Netherlands), a pharmaceutical-grade high-THC cannabis variant (21.8% THC; 0.1% cannabidiol), after placebo or oral oxycodone 20 mg pretreatment; THC was inhaled 1.5 and 4.5 h after placebo or oxycodone intake. The primary endpoint was isohypercapnic ventilation at an end-tidal Pco2 of 55 mm Hg or 7.3 kPa (VE55), measured at 1-h intervals for 7 h after placebo/oxycodone intake. RESULTS: In 18 volunteers (age 22 yr [3]; 9 [50%] female), oxycodone produced a 30% decrease in VE55, whereas placebo was without effect on VE55. The first cannabis inhalation resulted in VE55 changing from 20.3 (3.1) to 23.8 (2.4) L min-1 (P=0.06) after placebo, and from 11.8 (2.8) to 13.0 (3.9) L min-1 (P=0.83) after oxycodone. The second cannabis inhalation also had no effect on VE55, but slightly increased sedation. CONCLUSIONS: In humans, THC has no effect on ventilatory control after placebo or oxycodone pretreatment. CLINICAL TRIAL REGISTRATION: 2021-000083-29 (EU Clinical Trials Register.).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Leiden University Medical Center, Leiden, the Netherlands.
- Bedrocan International B.V., Veendam, the Netherlands.
- Department of Clinical Pharmacy, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands.
- Department of Anesthesiology, Leiden University Medical Center, Leiden, the Netherlands; PainLess Foundation, Leiden, the Netherlands. Electronic address: a.dahan@lumc.nl.
Zitieren
APA
van Dam, C. J., van der Schrier, R., van Velzen, M., van Lemmen, M., Simons, P., Kuijpers, K. W. K., Jansen, S., Kowal, M. A., Olofsen, E., Kramers, C., Dahan, A., & Niesters, M. (2023). Inhaled Δ9-tetrahydrocannabinol does not enhance oxycodone-induced respiratory depression: randomised controlled trial in healthy volunteers. British Journal of Anaesthesia. https://doi.org/10.1016/j.bja.2022.12.018
Vancouver
van Dam CJ, van der Schrier R, van Velzen M, van Lemmen M, Simons P, Kuijpers KWK, et al. Inhaled Δ9-tetrahydrocannabinol does not enhance oxycodone-induced respiratory depression: randomised controlled trial in healthy volunteers. British Journal of Anaesthesia. 2023. doi:10.1016/j.bja.2022.12.018
BibTeX
@article{vanDam2023,
author = {van Dam, Cornelis Jan and van der Schrier, Rutger and van Velzen, Monique and van Lemmen, Maarten and Simons, Pieter and Kuijpers, Kiki W K and Jansen, Simone and Kowal, Mikael A and Olofsen, Erik and Kramers, Cornelis and Dahan, Albert and Niesters, Marieke},
title = {Inhaled Δ9-tetrahydrocannabinol does not enhance oxycodone-induced respiratory depression: randomised controlled trial in healthy volunteers},
journal = {British Journal of Anaesthesia},
year = {2023},
doi = {10.1016/j.bja.2022.12.018}
}
EUVIMED